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Summary.-The T lymphocyte populations of 22 young healthy adults, 21 healthy
middle aged and older blood donors, 35 non-pregnant women of child bearing age
and 14 patients with advanced malignant disease were assessed and compared.
It was found that the mean T cell counts in the middle aged and older controls were
significantly lower than in the healthy young adults and were further reduced in
the patients with malignant disease. The addition of the proteolytic agent brinase
(protease 1 obtained from Aspergillus oryzae) to the rosetting test increased the T cell
counts significantly in all groups. This was most marked in the older age groups
and the patients with malignant disease. The proteolytic agent is shown to exert
its effect on the lymphocytes in the test. Slow intravenous infusion of either brinase
or streptokinase into patients with malignant disease is shown to result in increased
T lymphocyte counts pari passu with a restoration of skin allergy.
The significance of these findings and possible mode of action of the proteolytic
agents in increasing T cell activity are discussed.
THE THYMUS dependent lymphocyte
(T cell) is the basis of the cellular immune
mechanism and as such is associated with
the control of neoplasia and rejection
of tissue transplants. Depressed function
of the cellular immune mechanism
(anergy), as measured by skin tests for
delayed hypersensitivity, is found in a
high proportion of patients with cancer
in whom the prognosis is poor (Eilber and
Morton, 1970).
Immunotherapy cannot be expected
to be effective in an immunoincompetent
host and attempts to use immunotherapy
with B.C.G. have been shown to be
harmful in the anergic patient (Hunt et
al., 1973). The induction of proteolysis
(fibrinolysis) by protease 1 of Aspergillus
oryzae (Brinase, Astra AB, Sweden) en-
hanced skin tests for delayed hyper-
sensitivity in patients with cancer, who
were previously anergic (Thornes et al.,
1973). This prompted us to investigate
the effect of brinase in vivo and in vitro
on T lymphocytes in order to discover
whether the skin reactions were due to
increased skin sensitivity or due to direct
action of the enzyme on T lymphocytes.
Plant mitogens, phytohaemagglutinin
(P.H.A.) and concanavalin (Con A) (Ger-
gely et al., 1973a) have be3n shown to
have a direct E rosette enhancing effect
when incubated with lymphocytes. Pa-
pain (Chapel, 1973) has also been shown in
vitro to enhance the rosetting capacity
of lymphocytes whereas trypsin and
phospholipase A had the reverse effect.
MATERIAL AND AIETHODS
The spontaneous sheep red blood cell E
rosette test was employed to identify thymus
dependent lymphocytes (T cells) in the
peripheral blood. It is generally accepted
that the spontaneous E rosette test gives
a reliable indication of the numbers of
circulating T cells (Farid et al., 1974).
Ten ml blood samples were collected in
preservative-free heparin (20 i.u./ml) and
allowed to sediment at room temperature
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wNas layered on to a Ficoll-Hypaque gradient
(24 vol 9% Ficoll and 10 vol 33-9o Hypaque)
and lymphocytes were separated after centri-
fugation at 800 g for 10 min. The lympho-
cytes were wvashed twice in medium 199 and
adjusted to a concentration of 106/ml in
the same medium. 0(25 ml ofthis suspension
was mixed with an equal volume of a 0-5%
suspension of wvashed sheep red blood cells
(SRBC) and incubated at 37°C for 15 min.
The cell preparations were then centrifuged
at 200 g for 5 min at room temperature,
followAed by incubation at 4°C for 18 h.
The cells wAere resuspended and counted in a
Fuchs-Rosenthal haemacytometer. A mini-
mum of 200 lymphocytes were counted and
all lymphocytes binding 4 or more SRBC
wrere accepted as positive.
Duplicate samples of lymphocytes were
tested following treatment with brinase to a
final concentration of 0 9 mg/ml in medium
199, the brinase being added to the lympho-
cyte preparations and incubated at 22°C
for 20 min immediately before the addition
of the SRBC.
To determine whether the brinase affected
the SRBC or the lymphocytes, or both,
tests wvere set up using brinase pretreated
SRBC or brinase pretreated lymphocytes,
the cells being incubated at 22°C for 30 min,
followed by 2 washings, before being added
to the test system.
Because it has been shown that lympho-
cyte rosetting capacity can be influenced by
variations in temperature (Lay et al., 1971;
Chapel, 1973) and by the number ofwashings
to which the lymphocytes have been sub-
jected (Chapel, 1972), particular care was
taken to maintain reactions at 4°C and
limit the number of washings to 2. All
counts were performed by the same observer
and the test procedure did not vary at any
stage during the study.
Peripheral blood lymphocytes were exam-
ined from groups: (1) 22 healthy medical
students aged 18-29 years (12 male and 10
female); (2) 21 blood donors aged 40-65
years (13 male and 8 female); (3) 35 non-
pregnant women aged 21-43 years; (4) 14
patients (7 females, 7 males) aged 20-73
years writh advanced malignant tumours.
In Group 4, apart from testing the
rosetting capacity before and after the
addition of brinase to the test in vitro, the
patients' lymphocytes were tested in addition
immediately following a therapeutic dose of
13
either 100 mg of brinase or of streptokinase
(Streptase-Hoechst BehringwTerke A. G.,
Marburg-bahn, Germany) givenintravenously
in 200 ml saline over a period of one h.
The dose ofstreptokinase used N-as equivalent
to the streptokinase titre for the individual.
RESULTS
Group 1: 22 healthy medical students aged
18-29 years
The E rosetting capacity of lympho-
cytes in this group ranged from 45 to
76% (mean 61%, s.d. A10%). There
was no difference between the values
for males and females. Following the
addition of brinase in vitro the E rosetting
capacity was enhanced in 17 (77%o)
of the 22 students by an average of
9.500, which was statistically significant
(P < 0.05 > 002).
Group 2: 21 blood donors aged 40-65 years
In this group of healthy middle aged
blood donors the percentage of rosette
forming lymphocytes ranged from 11 to
72 (mean 42% A 17 s.d.). When com-
pared with Group 1 this reduction in
E rosetting capacity was statistically
significant (P < 0.001). Following the
addition of brinase in vitro the E rosette
TABLE I. Percentage of E Rosetting Lym-
phocytes in Various Groups
Group
1
2
3
4
Total
22
21
35
14
Ages
(years)
18-29
40-65
21- 43
20-73
Range (%)
45-76
11-72
38-83
17-56
MIean s.d.
61±10
42+ 17
(61 6±11-4
36±12-5
TABLE II. Effect of Brinase Added to in
vitro Test
% showing increasecl
Group rosetting
1 (17/22) 77
2 (19/21) 90
3 (26/35) 74
4 (12/14) 86
AMean increase (%)
9 5
12-0
12-8
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90
80
70
60
5C
4c
10
0
Non-pregnant
women
21-43 years
Medical students
18-29 years
FIG.-E rosetting lymphocyte population.
capacity increased in 19 (90%) of the
21 by an average of 12%, which was
statistically significant (P<001>0001).
Group 3: 35 non-pregnant women aged
21-43 years
The E rosetting capacity in this
group ranged from 38 to 83% (mean
61.6% s.d. + 11.4%). The addition of
brinase to the in vitro test resulted in
enhancement of the E rosetting capacity
in 26 (74%), the mean increase being
Patients with
Blood donors malignant neoplasms
40-65 years 20-73 years
12.8%, which was statistically significant
(P < 0.01 > 0.001).
Group 4: 14 patients with advanced malig-
nant disease aged 20-73 years
The E rosetting capacity of this
group ranged from 17 to 56% (mean
36% + 12.5% s.d.). The addition of
brinase to the in vitro test produced
significant enhancement of E rosetting
capacity in 12 (86%), the mean increase
being 24-4% (P < 0-01 > 0.001). When
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compared with the enhancement (120)
demonstrated in adults of similar age
(Group 2) this additional increase was
also statistically significant (P < 0 05 >
0.02).
Results following slow intravenous infusion
of proteolytic agents
Brinase infusion (9 patients treated).-
8 of the 9 patients showed higher post-
infusion percentage ofE rosetting lympho-
cytes than their initial levels. As ex-
pected, the addition of brinase to the in
vitro preinfusion assessment resulted in
a significant increase in E rosetting
capacity (P < 0 05 > 0.02).
Streptokina.se infusion (5 patients treat-
ed). All of the 5 patients treated showed
higher post-infusion percentages of E
rosetting lymphocytes than their initial
levels. The addition of brinase to the
in vitro preinfusion assessment resulted
in a significant increase in E rosetting
capacity (P < 0 01 > 0.001).
AntiplasMin levels and clot lysis times
After infusion, the mean antiplasmin
levels in the 14 patients with malignant
disease were reduced from 204.2% ± 3-4
to 121.4% 1 2*8 and the mean clot lysis
times were reduced from 10-8 h to 5 7 li
± 3 6. The lymphocyte counts were
lowered from a mean of 1800/mm3 to
1500/MMn3.
Site of action of brinase in E rosetting test
Brinase, when incubated with the
test sheep red cells for 30 min at 22°C
before washing, had nio E rosette enhanc-
ing effect in the subsequent in vitro
test. Conversely, the brinase treated
lymphocytes with untreated sheep red
cells showed enhanced rosetting capacity,
indicating that the proteolytic agent
induced some change in the rosetting
lymphocytes.
An interesting observation was that
the rosettes formed following the addition
of brinase were noted to be " tighter "
in aggregation than those occurring with
the untreated lymphocytes (Gergely et
al., 1973b).
D)ISCUSSION
Utilizing the spontaneous E rosette
test to evaluate the T cell population in
the peripheral blood, it has been reported
that for healthy adults there is a range
which varies between 500 and 90%o with
a suggested average of 650 (Farid et
al., 1974). It is accepted that even
minor variations in the technique em-
ployed may influence the values obtained
and that comparisons between different
workers' results are valid only if identical
techniques are followed.
The object of our investigation was
to determine the T cell values in healthy
adults of various ages and of patients
with malignant disease and to observe
the effects of proteolytic agents on the
T cell population both in vivo and in vitro.
A nuimber of observations appear
justified by the results of this investiga-
tion (Fig. and Tables I-IV). WVe have
found that the T cell counts of healthy
young adults are in general at a higher
level, average 6100, than in the 40-65
year age group which averaged 42% and
that the reduction in the older age group
was statistically significant (P < 0001).
The figure shows the clustering of the
results in the control groups and indicates
that T cell populations reduce with
increasing age. This is in agreement
with the findings of Augener et al. (1974)
that the absolute numbers of T lympho-
cytes showed a " striking decrease " in
old people. As expected, patients with
malignant disease showed a further reduc-
tion. There was no evidence of sex
differentiation in T cell counts in any
of the groups. A further observation
was that the addition of the proteolytic
agent brinase to the rosetting test in
vitro resulted in a statistically significant
enhancement of the T cell counts and
this effect was due to the action of the
brinase on the lymphocytes, the enhance-
ment being more marked in the older
age group.168 P. D. J. HOLLAND, 0. BROWNE AND R. D. THORNES
TABLE TII.-Effect of Brinase on T Lymphocyte Rosetting Capacity in vitro and in vivo
Diagnosis
Hypernephroma
Lymphosarcoma
Lymphosarcoma
Bronchogenic ea
Bronchogenic ca
Myeloma
Malignant melanoma
Myeloblastic leukaemia
Carcinomatosis
Sex Age
M
F
F
M
M
F
M
M
F
47
58
52
65
51
73
48
20
72
B3efore infusion in vitro test
{ ~~~A
Without brinase With brinase
(0) (0)
56
25
20
27
41
26
53
50
29
53
31
42
33
77
56
52
56
52
After infusion inl vitro test
Without brinase With brinase
(0) (0)
78
37
35
41
55
34
75
55
22
73
69
41
45
75
62
75
55
40
TABLE IV. Effect of Streptokinase on T Lymphocyte Rosetting Capacity in vitro and
in vivo
Diagnosis
Carcinomatous
Malignant melanoma
Bronchogenic ca
Lymphosarcoma
Ovarian ca
Sex Age
F
F
M
M
F
72
45
56
42
52
Before infusion in vitro test
Without brinase With brinase
(0)
47
38
41
38
17
(%o)
66
87
72
64
57
After infusioin in vitro test
Without brinase With brinase
(0)
60
69
49
51
40
(%o)
73
93
70
42
48
The effect of brinase in vitro on the
T cell counts in the group of patients
with malignant disease was surprising
though not unexpected (Thornes et al.,
1973): 86% of the patients showed
enhancement of the T cell counts with
an average of 24-5%o which is double
the increase found in healthy controls in
the same age group.
The T cell counts in the patients with
malignant disease were increased following
slow intravenous infusion with brinase
or streptokinase, confirming the in vivo
effect of the proteolytic enzymes. Eight
of the 9 brinase treated patients showed
an average increase of 13o6% and all 5
of the streptokinase treated patients
showed increased T cell counts, the average
increase being 1766%. In addition, 6
of the 9 brinase treated patients and
4 of the 5 streptokinase treated patients
showed a further T cell count enhance-
ment following the addition of brinase to
the in vitro test.
It is also interesting to record that the
rosettes formed in the brinase influenced
tests were largely of the " tight " type
(Dawkins and Zilko, 1973), suggesting
that the action of the proteolytic enzyme
is to unveil sheep cell receptors on the T
lymphocyte.
The results of this investigation sug-
gest that proteolytic agents both in vivo
and in vitro enhance the T cell counts in
healthy controls and more particularly
in patients with malignant disease. Chapel
(1973) has also shown that the enzyme
papain greatly increased the number of
rosette forming cells in vitro, trypsin and
phospholipase A having the reverse effect.
She suggests that papain acts by removing
material from the lymphocyte surface
which normally masks the sheep red cell
receptor and that this material is not re-
expressed by the cell. Papain may there-
fore act on the T lymphocyte membrane
in a fashion similar to that of brinase
and streptokinase activated plasmin.INFLUENCE OF PROTEOLYSIS ON E ROSETTE FORMING LYMPHOCYTES 169
The significance of the apparent in-
crease in T lymphocyte count is more
difficult to assess and the enhancement
ofthe receptor activity on the lymphocyte
membrane may not necessarily be equated
with enhanced immune functional activity.
It is interesting to report that all of
the patients with malignant tumours in
this investigation were anergic initially
when tested with PPD, streptokinase and
streptodornase. Following intravenous
infusion with either brinase or strepto-
kinase, skin reactivity was temporarily
restored in all of them pari passu with
the increase in T lymphocyte counts.
It appears reasonable to suggest that
the improvement induced in the T
lymphocyte counts by means of pro-
teolytic agents given intravenously may
be related to the improvement in the
patients' immunological status, as evi-
denced by a return of skin hypersensiti-
vity. One can only conjecture as to the
way in which proteolytic enzymes en-
hance the spontaneous rosetting capacity
of T lymphocytes. It has been suggested
(Chapel, 1973) that the mode of action
may be the unveiling of combining sites
on the lymphocyte membrane. It is
possible that a proportion of the com-
bining sites may be dormant or may be
coated with blocking antigens or antigen/
antibody complexes in the case of malig-
nant neoplasms and that the proteolytic
enzymes may activate or unblock the
sites to allow restoration to full function
of the T lymphocytes. The restoration
of skin allergy in patients with malignant
disease following infusion with brinase
or streptokinase suggests that the pro-
teolytic agents may act by increasing T
lymphocyte activity.
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